Published Online: Friday, September 1, 2006

The FDA has asked makers of antidepressants to modify their labels to include data about a rare but life-threatening lung problem—persistent pulmonary hypertension—that can affect babies born to women who take the drugs while pregnant. The agency also issued an alert about the potential risk of combining antidepressants with common migraine drugs. The alert warns that a life-threatening condition called serotonin syndrome may occur when the drugs are combined.

The FDA is investigating additional information on both risks and will issue further updates on the drugs' labels as information becomes available. "It is important to emphasize that the FDA recommends that women who are expecting and currently taking antidepressants should not discontinue use without first talking with a doctor," said Susan Bro, an FDA spokeswoman.

Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues